BTK and B-cell chronic lymphocytic leukemia: In the head-to-head phase 3 ALPINE trial (NCT03734016) of zanubrutinib versus ibrutinib in patients with R/R CLL/SLL, zanubrutinib demonstrated a superior ORR and PFS compared with the first-generation BTK inhibitor ibrutinib [10, 22].